Pemafibrate: First Global Approval

Drugs

Volumn 77, Issue 16, 2017, Pages 1805-1810

  Blair, Hannah A ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; MYOGLOBIN; PARMODIA; PEMAFIBRATE; (R)-2-(3-((BENZOXAZOL-2-YL-D4 (3-(4-METHOXYPHENOXY-D7)PROPYL)AMINO)METHYL)PHENOXY) BUTANOIC ACID; BENZOXAZOLE DERIVATIVE; BUTYRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN BINDING;

ADD ON THERAPY; ADVERSE EVENT; ALLERGY; ARTICLE; CHOLELITHIASIS; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG APPROVAL; HUMAN; HYPERLIPIDEMIA; KIDNEY DISEASE; MULTICENTER STUDY (TOPIC); MUSCLE WEAKNESS; MYALGIA; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; RHINOPHARYNGITIS; SIDE EFFECT; BLOOD; CHEMISTRY; DRUG EFFECT; GENETICS; LIPID METABOLISM; METABOLISM;

BENZOXAZOLES; BUTYRATES; CHOLESTEROL, HDL; DRUG APPROVAL; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIPOPROTEINS, HDL; PPAR ALPHA; PROTEIN BINDING;

EID: 85029588385     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-017-0818-x     Document Type: Article

References (16)

1. ® tab. 0.1 mg: prescribing information. 2017. www.kowa-souyaku.co.jp. Accessed 16 Aug 2017.
2. Takei K, Han SI, Murayama Y, et al. Selective peroxisome proliferator-activated receptor-alpha modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-alpha pathway and improves lipid metabolism in mice. J Diabetes Investig. 2017;8(4):446–52.
3. ® tablets 0.1 mg” about acquiring manufacturing and marketing approval in Japan. First time high active and highly selective PPARα modulator in the world]. 2017. http://www.kowa.co.jp. Accessed 16 Aug 2017.
4. Raza-Iqbal S, Tanaka T, Anai M, et al. Transcriptome analysis of K-877 (a novel selective PPARα modulator (SPPARMα))-regulated genes in primary human hepatocytes and the mouse liver. J Atheroscler Thromb. 2015;22(8):754–72.
5. Takei K, Nakagawa Y, Wang Y, et al. Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice. J Pharmacol Sci. 2017;133(4):214–22.
6. Hennuyer N, Duplan I, Paquet C, et al. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis. 2016;249:200–8.
7. Sairyo M, Kobayashi T, Masuda D, et al. A novel selective PPARα modulator (SPPARMα), K-877 (pemafibrate), attenuates postprandial hypertriglyceridemia in mice. J Atheroscler Thromb. 2017. doi:10.5551/jat.39693.
8. Yamashita S, Ishibashi S, Arai H, et al. Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on postprandial hyperlipidemia in dyslipidemic patients: a randomized cross-over study [abstract no. P5891]. Eur Heart J. 2016;37(Suppl 1):1204.
9. Yamashita S, Ishibashi S, Arai H, et al. Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on cholesterol efflux from macrophages in dyslipidemic patients [abstract no. P5982]. Eur Heart J. 2015;36(Suppl. 1):1047–8.
10. Araki E, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARα modulator (SPPARMα), on lipid and glucose metabolism in fasting and postprandial states in type 2 diabetic patients with dyslipidaemia [abstract no. 1112]. Diabetologia. 2016;59(Suppl. 1):S531.
11. Ishibashi S, Yamashita S, Arai H, et al. Efficacy and safety of K-877, a potent and selective PPAR-α agonist, in Japanese patients with dyslipidemia [abstract no. 10718]. Circulation. 2013;128(22 Suppl. 1).
12. Yamashita S, Ishibashi S, Arai H, et al. Comparison of the novel peroxisome proliferator-activated receptor alpha agonist K-877 and fenofibrate on high-density lipoprotein subclass distribution determined by high-performance liquid chromatography in patients with dyslipidemia [abstract no. 15652]. Circulation. 2013;128(22 Suppl. 1).
13. Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017;261:144–52.
14. Kastelein JJP, Senko Y, Hounslow N, et al. K-877, a selective PPAR alpha modulator (SPPARM alpha), ameliorates dyslipidaemia in patients with well-controlled LDL cholesterol levels on statin therapy, without increases in serum creatinine [abstract no. P5983]. Eur Heart J. 2015;36(Suppl. 1):1048.
15. Kastelein JJP, Senko Y, Hounslow N, et al. K-877, a selective PPAR alpha modulator (SPPARM alpha), improves dyslipidaemia in statin-treated patients with type 2 diabetes mellitus [abstract no. P5985]. Eur Heart J. 2015;36(Suppl. 1):1048.
16. Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36–43.